Mesotelioma

01Pathophysiology

Mesothelioma is a primary malignancy arising from the mesothelial cells that line the pleural, peritoneal, pericardial, or tunica vaginalis surfaces. The pleura is the most commonly affected site, accounting for roughly 80% of cases.

The disease is driven almost exclusively by asbestos fiber inhalation. Among asbestos subtypes, amphibole fibers (crocidolite, amosite) are far more carcinogenic than serpentine fibers (chrysotile) because of their rigid, needle-like shape. Once inhaled, these fibers penetrate deep into the distal airways and migrate to the pleural surface. Macrophages attempt to phagocytose the fibers but fail due to the fibers' length, resulting in frustrated phagocytosis. This triggers a chronic inflammatory cascade with persistent release of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which cause direct DNA damage, chromosomal aberrations, and activation of oncogenic signaling pathways such as NF-kB and PI3K/AKT.

A hallmark of asbestos-related carcinogenesis is the inactivation of tumor suppressor genes, particularly BAP1 (BRCA1-associated protein 1) and CDKN2A (p16). Loss of BAP1 function is found in approximately 60% of mesotheliomas and serves as both a diagnostic and prognostic marker. Germline BAP1 mutations also explain rare familial clustering of mesothelioma cases.

The extremely long latency period of 20 to 50 years is a direct reflection of this slow, cumulative process of inflammation, mesothelial cell injury, and eventual malignant transformation. This is why the classic vignette presents an elderly patient whose asbestos exposure occurred decades earlier.

The tumor grows along the pleural surface in a circumferential, rind-like pattern, progressively encasing and restricting the lung rather than forming a discrete parenchymal mass. This explains the insidious onset of dyspnea (from restrictive physiology and effusion) and chest wall pain (from direct tumor invasion of the intercostal nerves and chest wall structures). The associated pleural effusion is exudative and frequently hemorrhagic due to tumor vascularity and pleural surface erosion.

It is important to distinguish that asbestos exposure causes both benign and malignant pleural disease. Benign pleural plaques (calcified or noncalcified) are a marker of prior asbestos exposure but are not premalignant. They do not transform into mesothelioma. However, their presence on imaging confirms the exposure history and should raise clinical suspicion.

Notably, smoking does not independently cause mesothelioma. Smoking synergizes with asbestos to dramatically increase the risk of bronchogenic lung carcinoma (multiplicative risk), but this synergy does not apply to mesothelioma. This distinction is heavily tested.

02Classification and Clinical Manifestation

Histologic Subtypes

Anatomic Classification

Clinical Staging (Simplified)

03Diagnostic Workup

When a vignette presents an older patient with a remote history of asbestos exposure and a unilateral pleural effusion, the first step is imaging. A chest X-ray will typically show a large unilateral effusion, and you may notice pleural thickening or calcified plaques. However, chest X-ray alone cannot confirm mesothelioma.

The best initial imaging study is a contrast-enhanced CT of the chest. The hallmark CT finding is circumferential, nodular pleural thickening that encases the lung, often described as a "rind" or "sheet-like" growth along the pleural surface. This pattern is distinct from the discrete peripheral mass seen in bronchogenic carcinoma. Additional CT findings include involvement of the interlobar fissures, mediastinal pleural thickening, and ipsilateral volume loss.

The next step is thoracentesis to characterize the effusion. The fluid is exudative by Light's criteria and frequently hemorrhagic. However, pleural fluid cytology has poor sensitivity (approximately 26 to 32%), because mesothelial cells are difficult to classify as benign or malignant on cytology alone. A negative cytology does not rule out mesothelioma.

Because cytology is unreliable, the gold standard for diagnosis is tissue biopsy, ideally obtained via video-assisted thoracoscopic surgery (VATS). This allows direct visualization of the pleural surface and acquisition of adequate tissue. CT-guided percutaneous biopsy is an alternative but yields smaller samples.

The biopsy specimen must undergo immunohistochemistry (IHC), which is essential for two reasons: confirming mesothelial origin and excluding metastatic adenocarcinoma to the pleura.

The classic IHC profile for mesothelioma:

The mnemonic to recall: mesothelioma is calretinin-positive and CEA-negative, while adenocarcinoma is the opposite.

Once the diagnosis is confirmed, PET-CT is used for staging to evaluate for distant metastatic disease and to assess the contralateral hemithorax.

04Management and Treatment

Acute symptomatic management begins with addressing the pleural effusion. Large, symptomatic effusions causing dyspnea should be drained via therapeutic thoracentesis. For patients with recurrent effusions, talc pleurodesis (chemical sclerosing via thoracoscopy or bedside slurry) or placement of an indwelling pleural catheter provides long-term palliation.

For patients with early-stage, resectable disease and adequate cardiopulmonary reserve, the treatment of choice is a multimodal approach combining surgery with systemic chemotherapy. The preferred surgical procedure has shifted toward pleurectomy/decortication (P/D), which removes the visceral and parietal pleura while preserving the lung. This carries lower perioperative mortality compared to the more radical extrapleural pneumonectomy (EPP), which removes the lung, pleura, diaphragm, and pericardium en bloc. EPP is now reserved for highly selected cases.

The cornerstone of systemic therapy is pemetrexed combined with cisplatin. Pemetrexed (500 mg/m^2 IV) plus cisplatin (75 mg/m^2 IV) is administered every 21 days for up to 6 cycles. Patients receiving pemetrexed must be supplemented with folic acid (400 to 1000 mcg daily, starting 7 days before the first dose) and vitamin B12 (1000 mcg IM, given at least 7 days before the first cycle and every 9 weeks thereafter) to reduce the risk of severe myelosuppression and mucositis. Dexamethasone premedication (4 mg twice daily for 3 days, starting the day before infusion) is also standard to prevent skin rash.

For patients who cannot tolerate cisplatin (e.g., renal insufficiency, significant neuropathy), carboplatin (AUC 5) is substituted.

A landmark advancement in treatment is the use of immune checkpoint inhibitors. The combination of nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) has demonstrated an overall survival benefit compared to chemotherapy alone, particularly in patients with non-epithelioid (sarcomatoid or biphasic) histology. This regimen is now a first-line option for unresectable mesothelioma.

Radiation therapy in mesothelioma has a limited curative role due to the diffuse nature of the tumor. It is primarily used as adjuvant therapy post-surgery to reduce local recurrence, or as palliative radiation for chest wall pain or painful procedural tract metastases (prophylactic irradiation of biopsy/drain sites remains debated).

There is no established role for prophylactic treatment in asymptomatic individuals with a history of asbestos exposure. These patients should undergo clinical surveillance with periodic imaging and symptom monitoring.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get questions on mesothelioma wrong is by confusing it with bronchogenic lung carcinoma or by incorrectly associating smoking with mesothelioma risk. When a vignette describes a patient with asbestos exposure and a pleural effusion, students sometimes select "lung cancer" because they recall the asbestos-smoking synergy. The critical distinction: the asbestos-smoking multiplicative risk applies to bronchogenic carcinoma, not mesothelioma. Mesothelioma risk is driven by asbestos alone, and smoking does not increase mesothelioma risk.

A second common trap involves the diagnostic approach. Students often select pleural fluid cytology as the confirmatory test. While thoracentesis is an appropriate early step, cytology has notoriously poor sensitivity for mesothelioma. The correct answer for the gold standard is always tissue biopsy with immunohistochemistry. If a question asks for the "next best step" after a negative cytology in a patient with suspicious imaging, the answer is thoracoscopic biopsy, not repeat thoracentesis.

Third, students may confuse pleural plaques with mesothelioma. Calcified pleural plaques are a marker of prior asbestos exposure and are the most common radiographic manifestation of asbestos-related disease. However, plaques are benign and do not undergo malignant transformation. Their presence should raise suspicion for asbestos-related disease but does not constitute a diagnosis of mesothelioma.

Fourth, remember the IHC panel. When a question presents a pleural biopsy and asks you to distinguish mesothelioma from metastatic adenocarcinoma, the discriminator is: calretinin-positive and CEA-negative points to mesothelioma; calretinin-negative and CEA-positive (with TTF-1 positive) points to adenocarcinoma. This is one of the most consistently tested immunohistochemistry panels.

Finally, regarding treatment, the testable pearl is the pemetrexed-cisplatin combination as first-line chemotherapy and the mandatory supplementation with folic acid and vitamin B12 to prevent toxicity. Forgetting supplementation is a tested pitfall, as pemetrexed without folate supplementation causes severe myelosuppression.

The core competency being tested across mesothelioma questions is the ability to integrate an occupational exposure history with characteristic imaging and pathologic findings, correctly sequence the diagnostic workup from imaging through biopsy, and apply the immunohistochemical profile to distinguish this tumor from its closest mimics.